


AtriCure

Creating a World Class Afib Platform

**INVESTOR EDUCATION:
HYBRID AF THERAPY**

SEPTEMBER 2022





Forward Looking Statements

This presentation and oral statements made in connection with this presentation contain “forward-looking statements,” which are statements related to future events that by their nature address matters that are uncertain. Forward-looking statements address, among other things, AtriCure’s expected market opportunity, future business, financial performance, financial condition, and results of operations, and often contain words such as “intends,” “estimates,” “anticipates,” “hopes,” “projects,” “plans,” “expects,” “drives,” “seek,” “believes,” “see,” “should,” “will,” “would,” “can,” “opportunity,” “target,” and similar expressions and the negative versions thereof. Such statements are based only upon current expectations of AtriCure. All forward-looking information is inherently uncertain and actual results may differ materially from assumptions, estimates, projections or expectations reflected or contained in the forward-looking statements as a result of various risk factors.

Reliance should not be placed on forward-looking statements because they involve known and unknown risks, uncertainties and other factors which may cause actual results, performance or achievements to differ materially from those expressed or implied. These risks, uncertainties and other factors include, but are not limited to, those identified at <http://www.atricure.com/forward-looking-statements> and/or described in AtriCure’s Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q, particularly the “Risk Factors” sections thereof, as filed with the U.S. Securities and Exchange Commission and available at <http://www.sec.gov>.

With respect to all forward-looking statements, AtriCure claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Forward-looking statements speak only as of the date they are made. AtriCure undertakes no obligation, and does not expect, to publicly update or revise any forward-looking statements to reflect new information or future events or otherwise unless required by law.



We are
passionately
focused on
reducing the
global Afib
epidemic and
healing the lives
of those affected

Large Markets

Addressing an underserved and growing patient population

Strong Portfolio


Existing products and solutions driving consistent growth

Bright Future

Novel therapies supported by growing body of clinical evidence

CONVERGE: Long-standing Persistent Afib Patient Analysis

Freedom from AF/AFL/AT from 3-month blanking period through 12-months and 18-months



- **Superior outcomes with hybrid Convergent procedure** when compared to endocardial catheter ablation alone in patients with drug refractory long-standing persistent Afib, with majority of patients experiencing:
 - + **Over 100% improvement** at 18 months
 - + **Over 90% burden reduction** at 12 months
 - + **Freedom from Afib** through 12 months
- **Improved EP lab efficiency** demonstrated by reduction in endocardial ablation time as a result of adding epicardial ablation

Afib: A Serious Problem

Atrial Fibrillation (Afib) is an irregular heartbeat (or arrhythmia) that affects more than 37 million people worldwide.¹



8 Million

People estimated to have Afib in the US²



3.5 Million

People estimated to have long-standing persistent Afib in the US³



1 in 4 Adults

Over 40 will develop Afib in their lifetime⁴



Thank You!

AtriCure



References and Abbreviations

Note	Reference
1	European Heart Journal – Quality of Care and Clinical Outcomes (2021) 7, 574-582 doi: 10.1093/ehjqcco/qcaa061
2	The American Journal of Cardiology (2013), 112: 1142-1147
3	Medical management estimate: Colilia, et al. Estimates of Current and Future Incidence and Prevalence of Atrial Fibrillation in the U.S. Adult Population. Am Journal of Cardiology 2013, 112: 1142-1147 Persistent patient estimate: Berisso et al Epidemiology of atrial fibrillation: European perspective Clin Epidemiol. 2014; 6: 213–220
4	Lifetime risk for development of atrial fibrillation. Circulation, 110 (2004): 1042-1046. doi: 10.1161/01.CIR.0000140263.20897.42

Key Abbreviations

Afib or AF	Atrial Fibrillation
AA	Atrial Arrhythmia
AFL	Atrial Flutter
AT	Atrial Tachycardia
EP	Electrophysiologist
LS	Long-standing
PMA	Pre-Market Approval
RF	Radio Frequency